News

Article

FDA Accepts Resubmitted NDA for AXS-07 for Acute Treatment of Migraine

The FDA assigned a Prescription Drug User Fee Action date is January 31, 2025.

The FDA accepted a new drug application resubmission for AXS-07 for the acute treatment of migraine. The Prescription Drug User Fee Action date is now January 31, 2025.1

Migraine, FDA, New Drug, Novel Drug | Image Credit: Andrey Popov - stock.adobe.com

Image Credit: Andrey Popov - stock.adobe.com

AXS-07 is a novel, rapidly absorbed investigational medication consisting of molecular solubility enhanced inclusion complex (MoSEIC) meloxicam and rizatriptan. The mechanism of action involves inhibiting the calcitonin gene-related peptide (CGRP) release, reversing CGRP-mediated vasodilation. In response, it inhibits the neuroinflammation, pain signal transmission, and central sensitizations. The MoSEIC technology results in a shorter absorption rate while retaining the plasma half-life of the medication, according to the company.2

In a session at the 2024 American Academy of Neurology Annual Meeting, Melissa Rayhill, MD, FAAN, associate professor of neurology at the University of Buffalo Jacobs School of Medicine, said that migraine is often a whole body phenomenon, with neurological, sensory, autonomic, vestibular, cognitive, and gastrointestinal symptoms. Over 47 million Americans are reported to experience migraine, including 10% of school-age children experiencing. It is also the leading cause of disability for adults under the age of 50 worldwide.3

Investigators conducted 2 phase 3 clinical trials that were published in Neurology, intended to evaluate the efficacy of AXS-07 in patients with risk factors for inadequate treatment response to acute treatment of migraine. Risk factors included higher body mass index (BMI), allodynia, morning migraine, and history of depression. There were 2 clinical trials included in the pool were MOMENTUM and INTERCEPT with 1594 patients and 352 patients, respectively. The trials included individuals with a history of inadequate response to prior acute treatments. In MOMENTUM, individuals received AXS-07, rizatriptan, MoSEEIC meloxicam, or the placebo to treat a single migraine attack (moderate or severe intensity). For INTERCEPT, patients received either a single dose of AXS-07 or the placebo at the earliest sign of migraine pain (when pain was still mild).4

Key Takeaways

  1. AXS-07 is a novel investigational drug for the acute treatment of migraine.
  2. Two Phase 3 trials (MOMENTUM and INTERCEPT) evaluated AXS-07 in patients with risk factors for inadequate response to other migraine treatments.
  3. The FDA is reviewing the new drug application resubmission with a decision expected by January 31, 2025.

Investigators pooled the 2-hour pain freedom rates of the medication compared with the placebo for the patient populations, finding that the rates were 19.1% with AXS-07 compared with 9.9% the placebo for BMI, 23.3% and 11% for allodynia, 23.5% and 10.5% for morning migraine, and 23.1% and 5.9% for history of depression, respectively, according to the study authors.4

In an additional analysis in 2024, investigators found that AXS-07 demonstrated greater headache pain freedom at 23% compared with the placebo at 11% and 39% and 25%, respectively, for the most bothersome symptom at 2 hours. Further, there was sustained pain freedom between 2 and 24 hours at 18% and 8% as well as 48 hours at 16 and 7%, respectively. Rescue medication use also declined through 24 hours at 43% and 21%, respectively.5

Treatment-emergent adverse events (TEAEs) were experienced by 12.7% of individuals taking AXS-07 and 6.6% taking the placebo. The most common TEAEs for AXS-07 were nausea at 2.4%, somnolence at 2.1%, and dizziness at 1.9%.4,5

REFERENCES
1. Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine. News release. Axsome Therapeutics. September 4, 2024. Accessed September 9, 2024. https://finance.yahoo.com/news/axsome-therapeutics-announces-fda-acceptance-110000999.html
2. Axsome Therapeutics. AXS-07. 2024. Accessed September 9, 2024. https://www.axsome.com/axs-portfolio/pipeline/about-axs-07
3. Gallagher A. Migraine Treatment Comes in Different Forms, Allowing for Patient Preferences. Pharmacy Times. April 23, 2024. Accessed September 9, 2024. https://www.pharmacytimes.com/view/migraine-treatment-comes-in-different-forms-allowing-for-patient-preference
4. Tepper S, Lipton R, Chhabra A, Streicher C, Parks G, Tabuteau H. Combined Efficacy and Safety of AXS-07 (MOSEICTM Meloxicam and Rizatriptan) in Two Phase 3 Clinical Trials (P7-12.002). Neurology. April 9, 2024. doi:https://doi.org/10.1212/WNL.0000000000205655
5. Tepper S, Jones A, Chhabra A, Alter S, Thomas Z, Tabuteau H. Efficacy of AXS-07 (MOSEIC Meloxicam and Rizatriptan) in Patients with Risk Factors for Inadequate Response to Acute Migraine Medications (P13-12.001). Neurology. April 25, 2023. doi:https://doi.org/10.1212/WNL.0000000000203038
Related Videos
Pharmacist helping patient -- Image credit: Clayton D/peopleimages.com | stock.adobe.com
Pharmacist and a patient -- Image credit: Zamrznuti tonovi | stock.adobe.com
October is American Pharmacists Month.
American Pharmacist Month | Image Credit: Zoran Zeremski - stock.adobe.com
smiling indian male doctor or pharmacist in white coat with stethoscope and clipboard over drugstore background
Efficient healthcare supply chain management ensures timely delivery of medical supplies and medications
Pharmacy School, social media, non-traditional learning | Image Credit: Ахтем - stock.adobe.com
Children's doctor vaccinating little boy at home.
Image Credit: © jarun011 - stock.adobe.com
Image Credit: © Sweettymojidesign - stock.adobe.com